The return on investment in pharma research and development (R&D) has increased from the previous year, with GLP-1 drugs ...

with more moving through the regulatory pipeline. Although the goals were clear, coordination was lacking. The vaccine R&D ecosystem functioned like a “conductorless orchestra,” says Gerald ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and type 2 diabetes.

The company reaffirmed its 2025 financial targets, supported by a robust R&D pipeline and strategic investments in oncology and vaccines. While IRA-related impacts and market competition pose ...

Alnylam is on track to meet its ambitious “2-2-5” pipeline and platform expansion goal announced at R&D Day in 2023. This includes filing Investigational New Drug (IND) applications for nine ...

"INTREPID's analysis identifies the critical gaps that currently exist in the antiviral R&D pipeline, and where we can work together with our collaborators and partners to shine a light on potential ...

The Crop Sciences division, despite ongoing glyphosate litigation, holds significant upside potential due to its expansive R&D pipeline and market undervaluation. High leverage ratio constrains ...

I updated my ongoing DCF analysis, looking at the value of the core business, excluding unapproved treatments and the R&D pipeline. I made the following key assumptions: This DCF analysis yields a ...

R&D expenditures exceeded 20% of sales for the first time, driven by investments in Ipsen’s internal pipeline and external innovation. SG&A costs increased by 3.3%, reflecting commercial ...

as well as manufacturing innovations to improve efficiency – – Company will webcast its R&D Day event today at 9:00 a.m. E.T – "Alnylam is driving the field of RNAi therapeutics into the ...

The report also provides you with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular ...